<sup>18</sup>F-Fludeoxyglucose–Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer
Authors: Emma C. Gertsen, Hylke J. F. Brenkman, Richard van Hillegersberg, Johanna W. van Sandick, Mark I. van Berge Henegouwen, Suzanne S. Gisbertz, Misha D. P. Luyer, Grard A. P. Nieuwenhuijzen, Jan J. B. van Lanschot, Sjoerd M. Lagarde, Bas P. L. Wijnhoven, Wobbe O. de Steur, Henk H. Hartgrink, Jan H. M. B. Stoot, Karel W. E. Hulsewe, Ernst J. Spillenaar Bilgen, Marc J. van Det, Ewout A. Kouwenhoven, Donald L. van der Peet, Freek Daams, Nicole C. T. van Grieken, Joos Heisterkamp, Boudewijn van Etten, Jan Willem van den Berg, Jean Pierre Pierie, Hasan H. Eker, Annemieke Y. Thijssen, Eric J. T. Belt, Peter van Duijvendijk, Eelco Wassenaar, Hanneke W. M. van Laarhoven, Kevin P. Wevers, Lieke Hol, Frank J. Wessels, Nadia Haj Mohammad, Miriam P. van der Meulen, Geert W. J. Frederix, Erik Vegt, Peter D. Siersema, Jelle P. Ruurda, Jessy Joy van Kleef, Mariska Prins, Joyce Pijpers, Jerôme Profar, Stan Tummers, Kees de Mooij, Maaike van Dam, Monique Heijmans, Antoinette van Groenestyn, Edith Bouwmeester, Ilse Masselink, Damiana Beumer, Nel de Vries
Journal: JAMA Surgery (2021)

<h3>Importance</h3> The optimal staging for gastric cancer remains a matter of debate. <h3>Objective</h3> To evaluate the value of<sup>18</sup>F-fludeoxyglucose–positron emission tomography with computed tomography (FDG-PET/CT) and staging laparoscopy (SL) in addition to initial staging by means of gastroscopy and CT in patients with locally advanced gastric cancer. <h3>Design, Setting, and Participants</h3> This multicenter prospective, observational cohort study included 394 patients with locally advanced, clinically curable gastric adenocarcinoma (≥cT3 and/or N+, M0 category based on CT) between August 1, 2017, and February 1, 2020. <h3>Exposures</h3> All patients underwent an FDG-PET/CT and/or SL in addition to initial staging. <h3>Main Outcomes and Measures</h3> The primary outcome was the number of patients in whom the intent of treatment changed based on the results of these 2 investigations. Secondary outcomes included diagnostic performance, number of incidental findings on FDG-PET/CT, morbidity and mortality after SL, and diagnostic delay. <h3>Results</h3> Of the 394 patients included, 256 (65%) were men and mean (SD) age was 67.6 (10.7) years. A total of 382 patients underwent FDG-PET/CT and 357 underwent SL. Treatment intent changed from curative to palliative in 65 patients (16%) based on the additional FDG-PET/CT and SL findings. FDG-PET/CT detected distant metastases in 12 patients (3%), and SL detected peritoneal or locally nonresectable disease in 73 patients (19%), with an overlap of 7 patients (2%). FDG-PET/CT had a sensitivity of 33% (95% CI, 17%-53%) and specificity of 97% (95% CI, 94%-99%) in detecting distant metastases. Secondary findings on FDG/PET were found in 83 of 382 patients (22%), which led to additional examinations in 65 of 394 patients (16%). Staging laparoscopy resulted in a complication requiring reintervention in 3 patients (0.8%) without postoperative mortality. The mean (SD) diagnostic delay was 19 (14) days. <h3>Conclusions and Relevance</h3> This study's findings suggest an apparently limited additional value of FDG-PET/CT; however, SL added considerably to the staging process of locally advanced gastric cancer by detection of peritoneal and nonresectable disease. Therefore, it may be useful to include SL in guidelines for staging advanced gastric cancer, but not FDG-PET/CT.